Pomerantz LLP is investigating claims on behalf of investors of Acer Therapeutics Inc. (''Acer'' or the ''Company'') (ACER). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Acer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On June 25, 2019, Acer disclosed receipt of a Complete Response Letter (''CRL'') from the U.S. Food and Drug Administration (''FDA'') regarding its marketing application for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (''vEDS''). Acer advised investors that ''[t]he CRL states that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS'' and that ''Acer plans to request a meeting to discuss the FDA's response.'' On this news, Acer's stock price fell sharply during intraday trading on June 25, 2019.